ANTIBODIES FOR PREVENTION AND THERAPY: Edited by John R. Mascola and Richard A. KoupVectored antibody gene delivery for the prevention or treatment of HIV infectionDeal, Cailin E.; Balazs, Alejandro B. Author Information Ragon Institute of MGH, MIT and Harvard, Cambridge, Massachusetts, USA Correspondence to Dr Alejandro B. Balazs, Ragon Institute of MGH, MIT and Harvard, 400 Technology Sq. Room 992, Cambridge, MA 02139, USA. Tel: +1 857 268 7100; fax: +1 857 268 7142; e-mail: [email protected] Current Opinion in HIV and AIDS: May 2015 - Volume 10 - Issue 3 - p 190-197 doi: 10.1097/COH.0000000000000145 Buy Metrics Abstract Purpose of review To discuss recent progress in the use of vectors to produce antibodies in vivo as an alternative form of HIV prophylaxis or therapy. Instead of passive transfer of monoclonal antibody proteins, a transgene encoding an antibody is delivered to cells by the vector, resulting in expression and secretion by the host cell. This review will emphasize adeno-associated virus (AAV)-based strategies and summarize the evidence in support of this strategy as an alternative to traditional vaccines. We will highlight the major findings in the field and discuss the impact that this approach could have on the prevention, treatment and possibly eradication of HIV in patients. Recent findings In this emerging field, the emphasis has been on the use of vectors delivering antibodies as an alternative to the development of an HIV vaccine. However, recent findings suggest that AAV-delivered broadly neutralizing antibodies can suppress HIV replication. As such, a single injection of AAV could mediate long-term antibody expression to act as a long-lived therapeutic in the absence of antiretroviral drugs. Summary Vector-mediated antibody expression can both prevent transmission and inhibit the replication of established HIV infections. As such, it offers an alternative to immunogen-based vaccine design and a novel therapeutic intervention by enabling precise manipulation of humoral immunity. Success may enable not only the development of effective prevention against HIV but may also provide an alternative to a lifetime of antiretroviral drugs taken by those who are already infected. Copyright © 2015 Wolters Kluwer Health, Inc. All rights reserved.